Mesa Laboratories, Inc. (NASDAQ:MLAB) CFO Sells $441,399.00 in Stock

Mesa Laboratories, Inc. (NASDAQ:MLABGet Rating) CFO John Sakys sold 2,100 shares of the stock in a transaction dated Monday, January 23rd. The stock was sold at an average price of $210.19, for a total value of $441,399.00. Following the sale, the chief financial officer now directly owns 9,696 shares in the company, valued at $2,038,002.24. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Mesa Laboratories Price Performance

Shares of NASDAQ:MLAB traded down $6.39 during trading on Wednesday, reaching $189.85. 79,793 shares of the company’s stock traded hands, compared to its average volume of 83,806. Mesa Laboratories, Inc. has a fifty-two week low of $114.21 and a fifty-two week high of $293.87. The company has a quick ratio of 2.13, a current ratio of 2.80 and a debt-to-equity ratio of 0.53. The firm has a market cap of $1.01 billion, a PE ratio of -252.64 and a beta of 0.68. The company has a 50-day simple moving average of $175.95 and a 200-day simple moving average of $170.28.

Mesa Laboratories (NASDAQ:MLABGet Rating) last posted its earnings results on Thursday, November 3rd. The medical instruments supplier reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $1.24. Mesa Laboratories had a positive return on equity of 6.71% and a negative net margin of 1.78%. The firm had revenue of $58.75 million for the quarter, compared to analysts’ expectations of $53.24 million. As a group, analysts predict that Mesa Laboratories, Inc. will post 6.52 earnings per share for the current year.

Mesa Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 15th. Investors of record on Tuesday, February 28th will be issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.34%. The ex-dividend date is Monday, February 27th. Mesa Laboratories’s payout ratio is -84.21%.

Institutional Investors Weigh In On Mesa Laboratories

Institutional investors have recently bought and sold shares of the company. Point72 Hong Kong Ltd acquired a new stake in Mesa Laboratories in the 1st quarter worth about $27,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in Mesa Laboratories in the 2nd quarter worth about $41,000. Global Retirement Partners LLC boosted its holdings in Mesa Laboratories by 25.7% in the 2nd quarter. Global Retirement Partners LLC now owns 254 shares of the medical instruments supplier’s stock worth $52,000 after buying an additional 52 shares during the last quarter. Quadrant Capital Group LLC boosted its holdings in Mesa Laboratories by 2,650.0% in the 3rd quarter. Quadrant Capital Group LLC now owns 330 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 318 shares during the last quarter. Finally, KBC Group NV acquired a new stake in Mesa Laboratories in the 2nd quarter worth about $88,000. 93.00% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have weighed in on MLAB. Evercore ISI increased their price target on Mesa Laboratories to $166.00 in a research report on Tuesday, November 15th. StockNews.com cut Mesa Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday.

About Mesa Laboratories

(Get Rating)

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries.

Featured Articles

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.